Biobank Competitors

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Clear and confident health care decisions begin with questions. At Labcorp, we’re constantly in pursuit of answers. As a global leader of innovative and comprehensive laboratory services, we help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Our more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about Labcorp (NYSE: LH) at www.labcorp.com.

Sanguine Biosciences is accelerating personalized medicine by empowering patients with their healthcare data and facilitating participation in biomedical research. Sanguine actively bridges the gap between patients and researchers through direct-to-patient engagement, in-home collection of fully annotated biospecimens, apheresis product offerings, and a suite of biorepository services. Sanguine has supported translational, clinical, and cell & gene therapy research at 35 of the top 40 global pharmaceutical and biotechnology companies, shortening timelines and validating early-stage results to increase confidence and refine biomarkers in human trials. Four years in a row, Sanguine received the prestigious designation of a “Great Places to Work” company. In 2022, Sanguine was designated #2038 on the Inc. 5000 America’s Fastest Growing Private Companies list and achieved recognition on FORTUNE’s 100 Best Small Workplaces and Best Workplaces in Biopharma. Referenced in over 140 publications, Sanguine studies have appeared in high-impact journals, including Science, Nature, NEJM, Nature Medicine, and Science Translational Medicine. Popular media outlets featuring Sanguine include the Fox News Channel, The Washington Post, Inc.,The Boston Globe, Inc., and many others.